Shanghai Jianfa Zhixin Medical Technology Group Co., Ltd. Announcement on the Use of Part of Idle Raised Funds and Idle Self-owned Funds for Cash Management
The company and all members of the board guarantee that the information disclosed is true, accurate, complete, and free from false records, misleading statements, or major omissions.
Important Content Reminder:
- Types of Cash Management Products: Cash management products with high safety, good liquidity, and a maximum holding period of no more than 12 months that meet capital preservation requirements.
- Cash Management Quota and Duration: Up to 100 million RMB (inclusive) of idle raised funds and up to 200 million RMB (inclusive) of idle self-owned funds. The usage period shall not exceed 12 months from the date of approval by the board of directors. Funds can be rolled over within the above limits and duration, but the transaction amount at any point (including reinvestment of investment returns) shall not exceed the investment quota.
- Review Procedures Completed: This matter has been pre-reviewed by the sixth meeting of the audit committee of the third board and approved by the fourteenth meeting of the third board. The sponsor has issued a non-objection verification opinion on this matter.
- Special Risk Reminder: Although the company intends to choose cash management products with high safety and liquidity, the financial market is significantly influenced by macroeconomic factors, and market fluctuations may affect this investment. The company will intervene appropriately based on economic conditions and changes in the financial market; thus, the actual returns from short-term investments cannot be predicted. Investors are advised to pay attention to investment risks.
I. Basic Situation of Raised Funds
According to the China Securities Regulatory Commission's approval of the initial public offering registration of Shanghai Jianfa Zhixin Medical Technology Group Co., Ltd. (Zheng Jian Xu Ke [2025] No. 1337) and with the consent of the Shenzhen Stock Exchange, the company issued 63,193,277 shares of RMB ordinary shares (A shares) at an issue price of 7.05 RMB per share, raising a total of 445.5126 million RMB. After deducting issuance costs of 82.1781 million RMB (excluding tax), the actual net raised funds amount to 363.3345 million RMB. The raised funds were transferred to the company's designated account on September 22, 2025. Yongcheng Accounting Firm (Special General Partnership) verified the arrival of the raised funds and issued a "Verification Report" (Yongcheng Yan Zi [2025] No. 361Z0047). The company has stored the raised funds in a special account and signed a "Three/Four Party Supervision Agreement" with the bank where the special account is opened and the sponsor.
II. Investment Projects and Usage of Raised Funds
According to the "Prospectus for the Initial Public Offering and Listing on the Growth Enterprise Market of Shanghai Jianfa Zhixin Medical Technology Group Co., Ltd." and the announcement on adjusting the amount of raised funds for investment projects, the raised funds are intended for the following projects:
| Project Name | Project Investment Amount | Original Planned Investment Amount | Adjusted Investment Amount |
|---|---|---|---|
| Information System Upgrade Project | 140,159,500 RMB | 140,159,500 RMB | 105,000,000 RMB |
| Medical Consumables Intensive Operation Service Project | 104,077,600 RMB | 104,077,600 RMB | 78,000,000 RMB |
| Supplementing Working Capital | 240,000,000 RMB | 240,000,000 RMB | 180,334,500 RMB |
| Total | 484,237,100 RMB | 484,237,100 RMB | 363,334,500 RMB |